Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Continuing Operations: 2023-2025

Historic Income from Continuing Operations for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Income from Continuing Operations fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.38% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Income from Continuing Operations of -$19.7 million as of Q3 2025, which was up 35.02% from -$30.3 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Income from Continuing Operations ranged from a high of $35.8 million in Q3 2024 and a low of -$112.4 million during Q2 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median Income from Continuing Operations value was -$44.3 million (recorded in 2023), while the average stood at -$43.4 million.
  • Over the last 5 years, Day One Biopharmaceuticals' Income from Continuing Operations had its largest YoY gain of 177.66% in 2024, and its largest YoY loss of 165.16% in 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$54.5 million in 2023, then fell by 20.61% to -$65.7 million in 2024, then plummeted by 154.94% to -$19.7 million in 2025.
  • Its Income from Continuing Operations stands at -$19.7 million for Q3 2025, versus -$30.3 million for Q2 2025 and -$36.0 million for Q1 2025.